Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNIVERSAL1: Pharmacokinetic study of a novel dolutegravir/emtricitabine/tenofovir alafenamide dose ratio for children
PACTR202412742953806Phase 2Not yet recruiting
- Sponsor
- Penta Foundation
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of dolutegravir, emtricitabine and tenofovir alafenamide in Human immunodeficiency virus infection type 1, sponsored by Penta Foundation. Primary endpoint: Pharmacokinetics and short-term safety of DTG and FTC/TAF using a novel dose ratio. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
dolutegraviremtricitabinetenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on PACTR202412742953806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202412742953806.